Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT03122496 2022-06-08

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Phase 1 Completed

13 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT03292250 2022-03-29

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Phase 2 Completed

180 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03144778 2021-03-18

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Phase 1 Completed

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Phase 1 Completed

269 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT02369874 2021-02-10

EAGLE

Phase 3 Completed

736 enrolled 26 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02319044 2020-09-29

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

267 enrolled 27 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02262741 2017-10-23

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Phase 1 Completed

71 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck